Elite 50% OFF Act now – get top investing tools Register Now!

Cue Biopharma, Inc.

Contributing Author

Recent Articles by Cue Biopharma, Inc.

Nov-12	Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights CUE GlobeNewswire
Nov-06	Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors CUE GlobeNewswire
Sep-29	Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates CUE GlobeNewswire
Aug-21	Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference CUE GlobeNewswire
Aug-13	Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme CUE GlobeNewswire
Aug-12	Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights CUE GlobeNewswire
Jul-16	Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer CUE GlobeNewswire
Jul-01	Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies CUE GlobeNewswire
Jun-24	Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease CUE GlobeNewswire
May-12	Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights CUE GlobeNewswire
May-08	Cue Biopharma to Host Virtual Investor Event on May 15, 2025 CUE GlobeNewswire
May-05	Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference CUE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.